Summit Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Summit Therapeutics PLC
SMMT Stock  USD 18.94  0.26  1.35%   
Summit Therapeutics financial statements provide useful quarterly and yearly information to potential Summit Therapeutics PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Summit Therapeutics financial statements helps investors assess Summit Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Summit Therapeutics' valuation are summarized below:
Gross Profit
705 K
Market Capitalization
14 B
Enterprise Value Revenue
6.4 K
Earnings Share
(0.23)
Quarterly Revenue Growth
(1.00)
There are currently one hundred twenty fundamental trend indicators for Summit Therapeutics PLC that can be evaluated and compared over time across competition. All traders should double-check Summit Therapeutics' current fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 1.7 B in 2024. Enterprise Value is likely to gain to about 1.7 B in 2024

Summit Therapeutics Total Revenue

0.0

Check Summit Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Summit Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 95.3 M, Interest Expense of 17.3 M or Selling General Administrative of 31.8 M, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0 or PTB Ratio of 19.78. Summit financial statements analysis is a perfect complement when working with Summit Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Summit Therapeutics Correlation against competitors.

Summit Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets213.1 M202.9 M112.3 M
Slightly volatile
Total Current Liabilities11 M20.4 M13.6 M
Slightly volatile
Property Plant And Equipment Net6.4 M6.1 M1.8 M
Slightly volatile
Accounts Payable4.2 M2.7 M4.6 M
Pretty Stable
Cash47 M71.4 M54.7 M
Slightly volatile
Non Current Assets Total12.3 M13.2 M11.4 M
Slightly volatile
Cash And Short Term Investments195.6 M186.2 M72.3 M
Slightly volatile
Common Stock Total Equity706.2 K743.4 K3.5 M
Slightly volatile
Common Stock Shares Outstanding650.6 M619.6 M154.6 M
Slightly volatile
Liabilities And Stockholders Equity213.1 M202.9 M112.3 M
Slightly volatile
Non Current Liabilities Total110.1 M104.9 M54.1 M
Slightly volatile
Other Current Assets2.5 M2.6 M23.6 M
Slightly volatile
Other Stockholder Equity1.1 B1.1 B273.3 M
Slightly volatile
Total Liabilities131.5 M125.3 M68.2 M
Slightly volatile
Total Current Assets199.2 M189.7 M100.8 M
Slightly volatile
Intangible Assets7.4 M12 M7.9 M
Slightly volatile
Common Stock4.7 M7 M4.5 M
Slightly volatile
Net Receivables805.6 K848 K5.2 M
Pretty Stable
Property Plant And Equipment Gross7.5 M7.1 M2.2 M
Slightly volatile
Good Will3.6 M1.9 M2.9 M
Slightly volatile
Property Plant Equipment6.1 M5.8 M1.7 M
Slightly volatile
Other Liabilities1.2 M1.3 M6.3 M
Very volatile
Net Invested Capital192.7 M177.7 M94.7 M
Slightly volatile
Net Working Capital182.4 M169.3 M94.2 M
Slightly volatile
Capital Stock7.4 M7 M2.5 M
Slightly volatile

Summit Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization95.3 M90.7 M13.4 M
Slightly volatile
Interest Expense17.3 M16.5 M2.9 M
Slightly volatile
Selling General Administrative31.8 M30.3 M13.8 M
Slightly volatile
Other Operating Expenses94.2 M89.7 M42.8 M
Slightly volatile
Research Development62.4 M59.5 M35.3 M
Slightly volatile
Selling And Marketing Expenses1.6 M2.4 M2.3 M
Pretty Stable
Reconciled Depreciation2 M2 M1.2 M
Slightly volatile

Summit Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation1.3 M2 M975.7 K
Slightly volatile
Capital Expenditures121.6 K128 K229.3 K
Slightly volatile
Total Cash From Financing Activities56.5 M86.5 M71.6 M
Slightly volatile
End Period Cash Flow60.2 M71.4 M75.6 M
Slightly volatile
Stock Based Compensation14.8 M14.1 M4.5 M
Slightly volatile
Issuance Of Capital Stock4.8 M5 M46.2 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.3 K1.3 K4.3 K
Slightly volatile
Days Sales Outstanding155163801
Pretty Stable
Invested Capital25.1 M23.9 M24.5 M
Slightly volatile
Average Payables2.3 M4.3 M4 M
Slightly volatile
Stock Based Compensation To Revenue13.2612.633.3276
Slightly volatile
Capex To Depreciation0.05930.06240.7583
Slightly volatile
EV To Sales1.5 K1.6 K4.3 K
Slightly volatile
Inventory Turnover0.00910.00960.5832
Slightly volatile
Days Of Inventory On Hand41.4 K39.4 K14.1 K
Slightly volatile
Payables Turnover1.170.76872.0011
Pretty Stable
Sales General And Administrative To Revenue35.8334.1212.8594
Slightly volatile
Average Inventory60.4 K63.6 K43 K
Slightly volatile
Research And Ddevelopement To Revenue69.7766.4527.146
Slightly volatile
Capex To Revenue0.861.020.2776
Slightly volatile
Cash Per Share0.450.30060.5315
Slightly volatile
Days Payables Outstanding45147524.8 K
Slightly volatile
Net Current Asset Value113.8 K128.1 K139.5 K
Slightly volatile
Tangible Asset Value113.8 K128.1 K139.5 K
Slightly volatile
Intangibles To Total Assets0.00890.00930.1498
Slightly volatile
Current Ratio12.059.29737.8181
Pretty Stable
Receivables Turnover1.742.322.1304
Slightly volatile
Graham Number1.581.67322.256
Very volatile
Capex Per Share2.0E-42.0E-40.0038
Pretty Stable
Average Receivables8 M7.6 M3.9 M
Slightly volatile
Revenue Per Share0.00310.00330.1382
Pretty Stable
Days Of Payables Outstanding45147524.8 K
Slightly volatile
Ebt Per Ebit7.216.86321.7475
Slightly volatile
Long Term Debt To Capitalization0.790.56282.8427
Slightly volatile
Total Debt To Capitalization0.620.56282.6216
Slightly volatile
Quick Ratio11.589.29737.2314
Pretty Stable
Net Income Per E B T0.760.99850.9087
Pretty Stable
Cash Ratio3.333.50045.7149
Slightly volatile
Days Of Inventory Outstanding41.4 K39.4 K14.1 K
Slightly volatile
Days Of Sales Outstanding155163801
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.221.00171.0279
Slightly volatile
Fixed Asset Turnover0.150.1627.0798
Slightly volatile
Price Sales Ratio1.3 K1.3 K4.3 K
Slightly volatile
Asset Turnover9.0E-40.0010.1676
Slightly volatile
Operating Cycle41.5 K39.6 K14.7 K
Slightly volatile

Summit Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.6 B553.4 M
Slightly volatile
Working Capital113.8 K128.1 K139.5 K
Slightly volatile
Enterprise Value1.7 B1.7 B546 M
Slightly volatile

Summit Fundamental Market Drivers

Cash And Short Term Investments186.2 M

Summit Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Summit Therapeutics Financial Statements

Summit Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Summit Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Summit Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Summit Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue14.2 M14.9 M
Cost Of Revenue2 M1.9 M
Stock Based Compensation To Revenue 12.63  13.26 
Sales General And Administrative To Revenue 34.12  35.83 
Research And Ddevelopement To Revenue 66.45  69.77 
Capex To Revenue 1.02  0.86 
Ebit Per Revenue(117.71)(111.82)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY